| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Financial Outlook for the Full Year 2025
For the fiscal year ending December 31, 2025, the Company now expects total revenue to grow 24% to $760 million compared to the previous expectation of $742 million. This includes surgical revenue of $684 million and EOS revenue of $76 million. The Company now expects non-GAAP adjusted EBITDA of approximately $91 million compared to the previous expectation of $83 million.
Posted In: ATEC